Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?

by van Weely Sonja, Moors Ellen HM, Brabers Anne EM, de Vrueh Remco LA
Published 2011-09-01

From rationing to rationality: an n-of-one trial service for off-label medicines for rare (neuromuscular) diseases

by Weinreich Stephanie S, Vrinten Charlotte, Verschuuren Jan JGM, Uyl-de Groot Carin A, Kuijpers Marja R, Sterrenburg Ellen, Scholten Rob JPM, van Bezooijen Cees FRM, Timmen Marcel FTH, van Weely Sonja, Cornel Martina C
Published 2012-11-01